Session » (1442–1487) SLE – Diagnosis, Manifestations, & Outcomes Poster II

Date: Monday, November 13, 2023

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2023

9:00AM-11:00AM: Abstract Number: 1471

A Comparative Study of Lupus Nephritis Class II and IgA Nephropathy: Renal Disease Other Than Lupus Nephritis in Systemic Lupus Erythematosus Patients

9:00AM-11:00AM: Abstract Number: 1458

Activated Naïve DNA-Reactive B Cells in Lupus Nephritis Patients Are Increased and Associated with Disease Activity

9:00AM-11:00AM: Abstract Number: 1467

Antiphospholipid Antibodies and the Risk of Diffuse Alveolar Hemorrhage in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis

9:00AM-11:00AM: Abstract Number: 1448

Association of Disease Activity and Anti-Double Stranded DNA Antibodies Titers with Echocardiographic Parameters in Systemic Lupus Erythematosus Patients

9:00AM-11:00AM: Abstract Number: 1461

Association of Serum Analytes with SLE Cognitive Impairment Phenotypes Formed by Machine Learning: MMP-9, S100A8/A9, IL-6, IL-10, and NGAL

9:00AM-11:00AM: Abstract Number: 1474

Associations and Outcomes of Critical Peripheral Ischemia in Systemic Lupus Erythematosus (SLE): Data from Indian SLE Inception Cohort for Research (INSPIRE)

9:00AM-11:00AM: Abstract Number: 1465

Blood-dominant Disease in Older-onset Lupus: A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 1462

Cardiovascular Damage in Systemic Lupus Erythematosus Occurs at Early Stages of the Disease. Chronological Analysis of Damage Accrual in a Large Cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER)

9:00AM-11:00AM: Abstract Number: 1482

Change in the SLE Mortality Rate and Prevalence of Lupus Nephritis Overtime: Single Center Retrospective Study in Japan

9:00AM-11:00AM: Abstract Number: 1477

Clinical and Economic Burden of Herpes Zoster in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study

9:00AM-11:00AM: Abstract Number: 1450

Clinical Manifestations and Outcomes in Systemic Lupus Erythematosus Patients Who Received Antiviral Therapy During the COVID-19 Omicron Variant Wave: Results from a Single Center Cohort of Puerto Rico

9:00AM-11:00AM: Abstract Number: 1486

Clinical Outcomes in Patients Admitted for ST-Elevation Myocardial Infarction with vs Without Systemic Lupus Erythematosus: An Analysis from National Inpatient Sample Database (2015-2018)

9:00AM-11:00AM: Abstract Number: 1480

Demographic and Clinical Characteristics of Patients with LN: A Multicenter Study from the Gulf Region

9:00AM-11:00AM: Abstract Number: 1476

Discriminating Disease Flare from Infection in Febrile Patients with Systemic Lupus Erythematosus Admitted to a Safety-Net Hospital System: A Retrospective, Multicenter Study

9:00AM-11:00AM: Abstract Number: 1451

Evaluation of Changes in SLE Patients’ Phenotype at Disease Onset, and Assessment of Disease Activity, Damage and Therapy at Diagnosis and During Follow up in the Last Forty Years: Preliminary Data of a Single Center Experience

9:00AM-11:00AM: Abstract Number: 1449

Evaluation of Progression from Preclinical to Systemic Autoimmune Rheumatic Disease

9:00AM-11:00AM: Abstract Number: 1446

Glucocorticoids Use Is a Major Driver of Self-perceived Depression in Systemic Lupus Erythematosus: Insights from a Large, Prospective and Multicenter Study Using RELESSERPROS Register’s Database

9:00AM-11:00AM: Abstract Number: 1483

High Chronicity Index of the Modified NIH (National Institute of Health) Scoring System of Lupus Nephritis Is Associated with Increased Risk of End-stage Kidney Disease: A Retrospective Single-center Study

9:00AM-11:00AM: Abstract Number: 1444

Identifying Determinants of Favourable and Poor Physical Function in Systemic Lupus Erythematosus: Results from an International Collaborative Study

9:00AM-11:00AM: Abstract Number: 1466

Impact of Co-morbid Depression on Systemic Lupus Erythematosus Hospitalizations: Insights from National Readmission Database 2020

9:00AM-11:00AM: Abstract Number: 1460

Impact of Neuropsychiatric Involvement on Health-related Quality of Life in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1442

Incident Vascular Events in Danish Nationwide Cohort of Patients with Newly Diagnosed Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1447

Increased Left Ventricular Mass Index in Systemic Lupus Erythematosus Patients with Lupus Nephritis Compared to Those Without Nephritis

9:00AM-11:00AM: Abstract Number: 1452

Inflammatory Markers and Left Ventricular Dysfunction in Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 1464

Lupus Flares More Common in Patients on Dialysis Compared to After Renal Transplant: A Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 1473

Mortality from Diseases of the Nervous System in Patients with Lupus in the past Two Decades

9:00AM-11:00AM: Abstract Number: 1453

Musculoskeletal Involvement in Systemic Lupus Erythematosus: Insights from a Survey of Lupus Experts

9:00AM-11:00AM: Abstract Number: 1454

Neuropsychiatric Systemic Lupus Erythematosus in Children: A Scoping Review

9:00AM-11:00AM: Abstract Number: 1457

Obesity Is an Independent Poor Prognostic Factor in Lupus Nephritis

9:00AM-11:00AM: Abstract Number: 1468

Prediction of Cardiovascular Disease in Patients with Systemic Lupus Erythematosus Using a Machine Learning Algorithm for Time-to-Event Outcomes: Random Survival Forest

9:00AM-11:00AM: Abstract Number: 1463

Predictors of Cognitive Impairment in Individuals with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1478

Presentation and Outcomes of Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus: A Multicenter Cohort and a Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 1469

Prevalence of Cardiovascular Disease in a Populations Based Registry of Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1472

Prevalence of Hepatic Injury in Patients with Systemic Lupus Erythematosus: A 28-Year Single Center Experience

9:00AM-11:00AM: Abstract Number: 1487

Prevalence of Objectively Measured Sleep Disturbance in Systemic Lupus Erythematosus (SLE)

9:00AM-11:00AM: Abstract Number: 1481

Racial Disparities in Lupus Nephritis: A Nationwide Analysis

9:00AM-11:00AM: Abstract Number: 1475

Retrospective Study of Obesity on Clinical and Immunological Features in Systemic Lupus Erythematosus Using AI Software Deep 6 and EPIC Slicer Dicer

9:00AM-11:00AM: Abstract Number: 1479

Risk Factors for Human Papillomavirus Cervical Infection and Clearance in Patients with Systemic Lupus Erythematosus: The PAPILUP Study

9:00AM-11:00AM: Abstract Number: 1455

Risk Factors of Cytomegalovirus Reactivation and Disease in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1485

Risk of Diabetes Mellitus in Systemic Lupus Erythematosus: Systematic Review and Meta-analysis

9:00AM-11:00AM: Abstract Number: 1484

Ruminococcus Implicated in the Clinical Development of Lupus Nephritis: A Systematic Review of the Literature

9:00AM-11:00AM: Abstract Number: 1470

SARS-CoV-2 Antibody Formation After COVID-19 Vaccination in SLE Patients Treated with Belimumab: Single-Center Prospective Observational Study

9:00AM-11:00AM: Abstract Number: 1445

SLESIS-R: An Improved Score for Prediction of Serious Infection in Patients with Systemic Lupus Erythematosus Based on the RELESSER Prospective Cohort

9:00AM-11:00AM: Abstract Number: 1456

Systematic Review of Effects of Systemic Lupus Erythematosus on Brain Structure and Structural Connectivity and Its Relationship with Cognitive Dysfunction Through an Advanced Neuroimaging Lens

9:00AM-11:00AM: Abstract Number: 1459

Unveiling the Impact of Neuropsychiatric Involvement in Systemic Lupus Erythematosus on Damage Accrual

9:00AM-11:00AM: Abstract Number: 1443

Vasculitis Associations Among Patients with Systemic Lupus Erythematous

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].